Correction

Correction: Increased copy number at 3p14 in breast cancer

Ingrid Ljuslinder[1], Beatrice Malmer[1], Irina Golovleva[2], Marcus Thomasson[1], Kjell Grankvist[3], Thomas Höckenström[4], Stefan Emdin[5], Yvonne Jonsson[1], Håkan Hedman[1] and Roger Henriksson[1]

[1]Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
[2]Department of Medical Biosciences, Medical and Clinical Genetics, Umeå, Sweden
[3]Department of Medical Biosciences, Clinical Chemistry, Umeå University, Umeå, Sweden
[4]Department of Pathology, Umeå University, Umeå, Sweden
[5]Department of Surgical and Perioperative Sciences, Division of Surgery, Umeå University, Sweden

Corresponding author: Ingrid Ljuslinder, ingrid.ljuslinder@onkologi.umu.se

Published: 4 April 2006
This article is online at http://breast-cancer-research.com/content/8/2/405

Breast Cancer Research 2006, **8:**405 (doi:10.1186/bcr1409)

It was recently noticed that an error had been made in the research article by Ljuslinder and colleagues [1] published by *Breast Cancer Research* in July 2005. The legend of Table 4 was incorrect and should read as featured opposite.

Reference

1. Ljuslinder I, Malmer B, Golovleva I, Thomasson M, Grankvist K, Höckenström T, Emdin S, Jonsson Y, Hedman H, Henriksson R: **Increased copy number at 3p14 in breast cancer.** *Breast Cancer Research* 2005, **7:**R719-R727.

Table 4

EGFR and ERBB2 quantitative RT-PCR mRNA results in eight patients and matched controls (group B)

Patient number		T	NN	T/NN[a]
1[b]				
	EGFR	4,677	12,493	0.37
	ERBB2	24,066	21,817	1.1
2[b]				
	EGFR	3,321	14,519	0.22
	ERBB2	61,389	6,666	9.2
4				
	EGFR	20,778	14,842	1.39
	ERBB2	9,143	6,742	1.35
5[b]				
	EGFR	9,730	15,867	0.61
	ERBB2	13,506	3,056	4.41
6				
	EGFR	1,305	15,871	0.08
	ERBB2	10,677	10,080	1.06
7				
	EGFR	1,024	12,162	0.08
	ERBB2	7,639	5,871	1.30
8[b]				
	EGFR	4,936	28,111	0.17
	ERBB2	17,106	9,263	1.85
9				
	EGFR	5,540	1,437	3.85
	ERBB2	7,330	5,540	1.32

[a]T/NN: mRNA expression levels of EGFR/ERBB2 in tumour tissue (T) samples divided by values in in matched non-neoplastic (NN) tissue samples. As described in the results, at p.9, ratios >1.2 are regarded as significant overexpression and ratios <0.8 are regarded as significant underexpression in neoplastic tissue compared to non-neoplastic tissue. [b]Patients with increased *LRIG1* copy number. No RNA from patient 3 was available for EGFR/ERBB2 analysis.